BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/1/2024 7:39:37 AM | Browse: 172 | Download: 234
 |
Received |
|
2024-05-01 02:04 |
|
Peer-Review Started |
|
2024-05-01 02:04 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-05-25 01:31 |
|
Revised |
|
2024-05-27 17:54 |
|
Second Decision |
|
2024-06-12 02:41 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-06-12 05:56 |
|
Articles in Press |
|
2024-06-12 05:56 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-06-17 02:31 |
|
Publish the Manuscript Online |
|
2024-07-01 07:39 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Back to the drawing board: Overview of the next generation of combination therapy for inflammatory bowel disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jeffrey A Lowell, Michael J Farber and Keith Sultan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jeffrey A Lowell, MD, PhD, Doctor, Doctor, Department of Medicine, Zucker School of Medicine at Hofstra, North Shore University Hospital-Long Island Jewish Medical Center, 300 Community Drive, Manhasset, NY 11030, United States. jlowell@northwell.edu |
| Key Words |
Inflammatory bowel disease; Biologics; Immunomodulators; Dual-therapy; Combination therapy |
| Core Tip |
Triantafillidis et al thoroughly collate important studies summarizing the available evidence supporting the combination of various therapeutics used in the treatment of inflammatory bowel disease (IBD). Specifically highlighted is the importance of exploring combination therapy with biologics and immunomodulators, and in particular the emerging role of dual-biologic therapy (DBT). Given that current evidence for DBT is limited and new biologics continue to be developed, there is an urgent need for high-quality prospective trials to establish new treatment paradigms for the next generation of IBD care. |
| Publish Date |
2024-07-01 07:39 |
| Citation |
<p>Lowell JA, Farber MJ, Sultan K. Back to the drawing board: Overview of the next generation of combination therapy for inflammatory bowel disease. <i>World J Gastroenterol</i> 2024; 30(25): 3182-3184</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i25/3182.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i25.3182 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
